(firstQuint)Study to Compare the Safety and Efficacy of UB-851 and Eprex.

 This is a 52-week, phase III trial consisting of two parts: Part I is designed as a double-blind, randomized, multicenter, parallel-group study to evaluate the efficacy and safety of UB-851 in comparison to Eprex(R) in subjects with renal anemia on hemodialysis with a treatment period of 24 weeks.

 Part II is designed as a single-arm, safety evaluation period (from week 25 to week 52) to evaluate the long-term safety and immunogenicity of UB-851.

.

 Study to Compare the Safety and Efficacy of UB-851 and Eprex@highlight

The primary objective of this study is to evaluate a 1:1 dose conversion from Eprex(R) to UB-851 in terms of clinical efficacy and safety in subjects with chronic renal failure receiving hemodialysis.

